閻水忠博士于2015年9月加入再鼎醫(yī)藥，目前擔任再鼎醫(yī)藥全球研發(fā)首席運營官。 加入再鼎之前，閻水忠博士是科文斯公司早期研發(fā)上海研發(fā)中心負責人，全面負責公司在中國的相關業(yè)務。2009年至2012年期間，閻水忠博士是和記黃埔醫(yī)藥公司藥物安全性評價和項目管理負責人。加入和記黃埔醫(yī)藥之前，閻水忠博士在美國輝瑞積累了豐富的經(jīng)驗。在其職業(yè)生涯中，閻水忠博士參與過多個候選藥物的IND和NDA申請工作，積累起與數(shù)個國家的衛(wèi)生注冊機構合作的豐富經(jīng)驗。 閻水忠博士擁有北京協(xié)和醫(yī)科大學博士學位，并在美國芝加哥大學Ben-May癌癥研究所完成博士后研究。閻水忠博士是美國毒理學會認證專家、中國毒理協(xié)會理事會理事、藥物毒理與安全性評價專業(yè)委員會委員、中國藥理學會藥物毒理專業(yè)委員會委員及中國醫(yī)藥創(chuàng)新促進會藥物研發(fā)專業(yè)委員會副主任委員。 ??? James Yan, Ph.D., joined Zai Lab in September 2015 and currently serves as Chief Operating Officer, Global R&D. Prior to joining Zai Lab, Dr. Yan was the head of the Covance early development Shanghai site, where he was responsible for all aspects of the business. Between 2009 and 2012, Dr. Yan served as the head of drug safety evaluation and program management of Hutchison Medi-Pharma. Prior to Hutchison Medi-Pharma, Dr. Yan had significant experience at Pfizer in the United States. Over the course of his career, Dr. Yan was involved in many IND and NDA filings for multiple drug candidates and gained substantial experience working with regulatory agencies in several countries. Dr. Yan holds a Ph.D. from Peking Union Medical University and completed post-doctoral training at the University of Chicago’s Ben-May Institute for Cancer Research. He is a diplomat of the American Board of Toxicology (DABT), a council member of the China Society of Toxicology and a member of the Drug Toxicity and Drug Safety Evaluation Committee, a member of Pharmaceutical Toxicology Committee of China Pharmacology Society and vice chairman of Drug R&D Committee of China Pharmaceutical Innovation and Research Association (PhIRDA). |